EACR and Fluidigm co-sponsor a European research award for high-dimensional spatial profiling
The European Association for Cancer Research (EACR) and Fluidigm are accepting immuno-oncology research proposals involving Imaging Mass Cytometry™ (IMC™) to gain a deeper understanding of the intricacies of the immune and tumor microenvironment. Grants will be awarded to the two most impactful proposals focusing on any type of cancer.
Researchers use IMC to explore the spatial distribution of cell types within the context of a tissue to gain new insights into phenotypes, immune response and disease mechanisms. IMC enables highly multiplexed immunohistochemistry studies of over 40 markers simultaneously at subcellular resolution.
These grants will provide researchers with the possibility of staining human FFPE tissue slides with a panel of more than 25 markers, including a core set of 18 markers. The panel can be used to stain a broad array of immune and non-immune cell types, and can be customized with an additional 5 antibodies selected from an extensive catalog of pathologist-verified Maxpar® antibodies. See what can be achieved with the flexibility of IMC panel design in the profiling of human tissue.
The competition is open to EACR members and nonmembers. One of the two grants will be awarded to a current EACR member. If a nonmember is granted the second award, that researcher will receive a one-year EACR membership, paid in full by Fluidigm.
Uncover biology’s hidden secrets:
- Identify new spatial signatures by focusing on your specific phenotypes or functional markers of interest by taking advantage of your unique selection of Maxpar catalog antibodies. Look at phosphorylation states, signaling pathways or exhaustion markers. Analyze the biology that is important for you.
- Identify unique single-cell signatures with our proprietary IMC Cell Segmentation Kit. Get robust data that you can trust.
- Receive single-cell phenotypic analysis and the original image files to delve deeper into the data uncovered using IMC.
- Win one of two free spatial profiling projects with IMC, powered by CyTOF® technology.
| Metal | Marker | Clone | Subpopulation | |
|---|---|---|---|---|
| Maxpar Human Tissue Architecture IMC Panel Kit | 141Pr | Alpha-smooth muscle acting | 1A4 | Myofibroblasts, pericytes |
| 169Tm | Collagen 1 | Polyclonal | Connective tissue | |
| 158Gd | E-cadherin | 24E10 | Epithelial cells | |
| 171Yb | Histone 3 | D1H2 | Nucleated cells | |
| 143Nd | Vimentin | D21H3 | Mesenchymal cells | |
| Maxpar Human Immune Activation IMC Panel Kit | 167Er | Granzyme B | EPR20129-217 | NK and T cells |
| 168Er | Ki-67 | B56 | Cycling cells | |
| 165Ho | PD-1 | EPR4877(2) | T follicular helper cells, activated T cells | |
| 150Nd | PD-L1 | SP142 | Activated macrophages, dendritic cells, T and B cells | |
| Maxpar Human Immune Activation IMC Panel Kit | 161Dy | CD20 | H1 | B cells |
| 170Er | CD3 | Polyclonal | T cells | |
| 156Gd | CD4 | EPR6855 | Helper T cells | |
| 173Yb | CD45RO | UCHL1 | Memory lymphocytes | |
| 159Tb | CD8a | KP1 | Dendritic cells, macrophage/monocytes, granulocytes | |
| 162Dy | CD68 | CD8/144B | Cytotoxic T cells | |
| 155Gd | FoxP3 | 236A/E7 | T regulatory cells | |
| 148Nd | Pan-keratin | C11 | Keratinocytes | |
| 191Ir/193Ir | Nucleic acid | N/A | Nucleated cells | |
| Innovative Solutions IMC Cell Segmentation Kit | 195Pt ICSK1 | Membrane marker | NA | Cell segmentation markers |
| 196Pt ICSK2 | Membrane marker | NA | Cell segmentation markers | |
| 198Pt ICSK3 | Membrane marker | NA | Cell segmentation markers |
Award details:
- Grant winners can select a panel from our Maxpar Immuno-Oncology IMC Panel Kit and ready-to-use, pathologist-verified Maxpar antibodies to stain up to 8 regions of interest on two slides (excluding titration slides).
- A Fluidigm Application Specialist will assist grant winners with sample processing and staining.
- Samples will be shipped to the Institute of Medical Immunology. Martin Luther University Halle-Wittenberg, where they will be acquired with a Hyperion™ Imaging System.
- Fluidigm will provide the grant winner with a single-cell phenotypic analysis and the original TIFF and MCD files.
Instructions to apply:
- Complete the proposal questionnaire to apply (see terms and conditions below):
- Submission must be received by 23:59 BST on May 27, 2022.
- Check out the Hyperion Imaging System and our Imaging Mass Cytometry reagent websites for details on Fluidigm Imaging Mass Cytometry tools.
Terms and Conditions
Publication of Project Results:
All grant submissions are confidential to the individual submitter and will not be published or distributed, provided, however, that Fluidigm and the EACR may share them with their own staff and distributors who will not disclose to a third party.
Applications will be reviewed by EACR Board Members and representatives of Fluidigm. One winner will be a member of the EACR, and if a non-EACR member is selected, they will be offered free of charge an annual membership to join the EACR, which will be paid for in full by Fluidigm.
Upon project completion, the grant winner agrees to participate in at least one of the following activities relating to the specific project, with specific details of the applicable activity to be mutually agreed upon in good faith by Fluidigm, the EACR and the winner: webinar, case study, blog post, presentation, or poster presentation. The winner agrees that Fluidigm and the EACR shall have the right to publicly announce the winner’s name and research title, and use anonymized data from the winner's projects in application notes including in marketing materials and -seminars. No public display of data will happen without previous written consent from the winner.
Eligibility and Requirements:
- Applicants must be actively enrolled or employed at a research institution in a capacity in which they perform life science research and have the ability to ship stained samples within 30 days of award notification.
- Members of the immediate families of the EACR and Fluidigm employees and directors, including the members of the panel of judges selecting the winners, and/or persons living in the same household as such persons, are ineligible to participate in this grant program.
- Applicants must not be government employees or a Healthcare Professional (HCP). Employees of government institutions and Healthcare Professionals should not be eligible to participate in the program. A Healthcare Professional is anyone who is: authorized or licensed to provide healthcare services to patients; involved in providing healthcare services to patients (e.g., clinical laboratory directors); or involved in the decision to purchase, prescribe, order, or recommend medical technologies or related services.
- This program is void where prohibited or otherwise restricted by law.The grant winners will have the possibility of staining up to 2 slides (excluding titration slides), and selecting up to 8 regions of interest of 1 square millimeter, which will be stained using a combination of our Maxpar Immuno-Oncology Panel Kit, our IMC Cell Segmentation Kit and a selection of 5 antibodies from our catalogue of pathologist-verified Maxpar antibodies. The final panel will be decided together after consulting with a Fluidigm Field Application Specialist.
- The required reagents from other suppliers (as specified in the Imaging Mass Cytometry Staining Protocol for FFPE Tissue Sections) will have to be provided by the applicant.
- The staining of the applicant samples will be performed together with the aid of a Fluidigm Application Specialist.
- Fluidigm will give all information regarding shipment of samples to the site of acquisition and the applicants must be capable of sending all necessary information regarding the sample (including digital images of the slide to guide image selection) to the Fluidigm Application Specialist, as required.
- Applicants must be based in Europe (or Israel).
Miscellaneous:
All grant applicants agree that Fluidigm may process the personal data he or she provides as part of application, only for the needs of the application and grant competition process, and in accordance with Fluidigm’s privacy policy available at https://www.fluidigm.com/legal/privacy
Please find the EACR privacy policy here: https://www.eacr.org/privacy-policy
The grant award winner may be required to sign and return an affidavit of eligibility, release of liability, a publicity release, and other appropriate legal documentation reasonably requested by Fluidigm. No substitution or transfer of the awarded prize is allowed except as permitted by Fluidigm. The award winner is responsible for any local tax liability (city, state, or federal) occurred by winning and accepting the award. If, for any reason, the grant program may not run as planned for any causes beyond the reasonable control of Fluidigm, then Fluidigm reserves the right in its sole discretion to cancel, terminate, modify or suspend the grant program. These terms and conditions and any action related to this grant program will be governed by the laws of the State of California, U.S.A, without regard to or application of its conflict of law provisions or your state or country of residence. All claims, legal proceedings or litigation arising in connection with these terms and conditions and this grant program will be brought solely in the federal or state courts located in San Francisco, State of California, U.S.A., and all applicants consent to the jurisdiction of and venue in such courts and waive any objection as to inconvenient forum. By participating in this grant program, each applicant unconditionally accepts and agrees to comply with and abide by these terms and conditions.
DISCLAIMERS. ANY ITEMS PROVIDED BY FLUIDIGM TO THE GRANT WINNERS ARE DELIVERED TO THE WINNERS “AS IS,” WITHOUT WARRANTY OF ANY KIND, NATURE OR DESCRIPTION, EXPRESSED OR IMPLIED, INCLUDING WITHOUT LIMITATION, WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Without limiting the generality of the preceding sentence, unless otherwise expressly stated in writing by Fluidigm, no claim or representation is made or intended: (i) as to any clinical use of any product provided herein (whether diagnostic, prognostic, therapeutic, blood banking or any other clinical use); (ii) that any product provided herein has been cleared, approved, registered or otherwise qualified by Fluidigm with any regulatory agency for use in any clinical procedure or for other use requiring compliance with any federal, state, provincial, European or any other governmental agency or regulatory body regulating diagnostic, therapeutic, blood or other clinical products, medical devices or similar products (iii) that any product provided herein will satisfy the requirements of any governmental body or other organization, including but not limited to the United States Food and Drug Administration or the International Organization for Standardization; or (iv) that any product provided herein or its performance is suitable or has been validated for any specific use or application.
LIABILITY. Neither Fluidigm nor the EACR can be held liable for any damage caused to the grant applicants or grant winners as a consequence of the implementation of the grant competition, or relating to the items provided by Fluidigm to the grant winners, except when provided otherwise by mandatory applicable law.